SwePub
Sök i LIBRIS databas

  Extended search

WFRF:(Massie R)
 

Search: WFRF:(Massie R) > (2009) > Rationale and desig...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist
  • Hernandez, A. F. (author)

Rationale and design of the Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure Trial (ASCEND-HF)

  • Article/chapterEnglish2009

Publisher, publication year, extent ...

  • 2009

Numbers

  • LIBRIS-ID:oai:gup.ub.gu.se/95487
  • https://gup.ub.gu.se/publication/95487URI

Supplementary language notes

  • Language:English

Part of subdatabase

Classification

  • Subject category:ref swepub-contenttype
  • Subject category:art swepub-publicationtype

Notes

  • BACKGROUND: Acute decompensated heart failure (ADHF) is a major public health burden with significant mortality and morbidity. Nesiritide is a recombinantly produced intravenous formulation of human B-type natriuretic peptide that promotes vasodilation and increases salt and water excretion, which results in reduced cardiac filling pressures. Prior studies have shown that dyspnea is improved in patients with ADHF 3 hours after nesiritide infusion with significant dose-related reductions in cardiac filling pressures and systemic vascular resistance without significant arrhythmias. However, the effect of nesiritide on dyspnea at 6 or 24 hours is unknown, and no clinical outcome trials have been done to provide a reliable estimate of the effect of nesiritide on morbidity and mortality. METHODS: The Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure trial (ASCEND-HF) is a phase III study evaluating the efficacy and safety of nesiritide in patients with ADHF. Patients hospitalized for hear failure will be randomly assigned to receive either intravenous nesiritide or matching placebo for 24 hours to 7 days. The 2 coprimary end points are (1) assessment of acute dyspnea at 6 or 24 hours and (2) death or rehospitalization for hear failure within 30 days. A total of 7,000 patients will be enrolled worldwide between 2007 and 2010. CONCLUSIONS: The data from the ASCEND-HF trial will establish whether nesiritide safely improves acute dyspnea as well as morbidity and mortality at 30 days.

Subject headings and genre

Added entries (persons, corporate bodies, meetings, titles ...)

  • O'Connor, C. M. (author)
  • Starling, R. C. (author)
  • Reist, C. J. (author)
  • Armstrong, P. W. (author)
  • Dickstein, K. (author)
  • Lorenz, T. J. (author)
  • Gibler, W. B. (author)
  • Hasselblad, V. (author)
  • Komajda, M. (author)
  • Massie, B. (author)
  • McMurray, J. J. (author)
  • Nieminen, M. (author)
  • Rouleau, J. L. (author)
  • Swedberg, Karl,1944Gothenburg University,Göteborgs universitet,Institutionen för medicin, avdelningen för akut och kardiovaskulär medicin,Institute of Medicine, Department of Emergeny and Cardiovascular Medicine(Swepub:gu)xsweka (author)
  • Califf, R. M. (author)
  • Göteborgs universitetInstitutionen för medicin, avdelningen för akut och kardiovaskulär medicin (creator_code:org_t)

Related titles

  • In:Am Heart J157:2, s. 271-71097-6744

Internet link

Find in a library

  • Am Heart J (Search for host publication in LIBRIS)

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view